Biosimilar Antibodies

Briquilimab (JSP-191) is a humanized monoclonal antibody engineered to target CD117 (c-Kit), facilitating the depletion of hematopoietic stem cells (HSCs). This antibody is characterized by its non-toxic profile, making it an ideal agent for clearing host marrow niche spaces. The primary application of Briquilimab is to enhance donor HSC engraftment and promote immune reconstitution, particularly in the treatment of severe combined immunodeficiency (SCID). This mechanism not only supports effective hematopoietic transplantation but also ensures safety and efficacy in clinical settings.

Bulumtatug is a human IgG1κ monoclonal antibody targeting Nectin-4. The recommended isotype control for experimental use is Human IgG1 kappa Isotype Control.

Urtoxazumab (TMA-15) is a humanized monoclonal antibody specifically targeting Shiga toxin 2 (Stx2). This antibody is designed to neutralize Stx2, a potent toxin produced by certain pathogenic strains of bacteria, thereby mitigating its effects in various biological and pathological processes. Urtoxazumab is utilized primarily in research focused on bacterial infections, particularly those involving Shiga toxin-producing organisms, and is instrumental in studying the mechanisms of toxin-induced cellular damage and the evaluation of therapeutic interventions.

Felmetatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets VTCN1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-MHC Class I Antibody (W6/32) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human MHC Class I molecules. For accurate isotype control in experimental procedures, it is recommended to use the Mouse IgG2a kappa, Isotype Control with this antibody. This product is essential for research focusing on the immune response, antigen presentation, and cellular immunity.

The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG4 kappa Isotype Control is recommended. This product is essential for research focused on the biological pathways mediated by VEGFR2/KDR/CD309, including angiogenesis and vascular development, making it highly relevant in studies of cancer, cardiovascular diseases, and other angiogenesis-related disorders.

Envafolimab (ASC 22; KN 035) is a recombinant fusion protein comprising a humanized single-domain anti-PD-L1 antibody linked to the Fc fragment of a human IgG1 antibody. This biologic is designed to inhibit the interaction between PD-L1 and PD-1, exhibiting an IC50 value of 5.25 nM, indicative of its potent inhibitory activity. Envafolimab is primarily utilized in research focused on solid tumors, providing a valuable tool for investigating the therapeutic potential of PD-L1 blockade in oncology.

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody designed to target a specific variant of the MUC5AC glycoprotein. This antibody exhibits high specificity for tumor-associated MUC5AC variants frequently expressed in colorectal and pancreatic cancers. Ensituximab's targeted mechanism of action makes it a valuable tool for research focused on these types of malignancies, providing potential insights into disease pathways and therapeutic approaches.

Zeripatamig is a human IgG1 κ monoclonal antibody targeting both CD19 and CD47 antigens. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Atenastobart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets TNFRSF9. For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control.

LY2525623 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-23 (IL-23). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Ragistomig is a monoclonal antibody of the IgG1 isotype, specifically targeting TNFRSF9/CD274. It is composed of two identical IgG1 heavy chains and a κ light chain paired with a variable region that includes a λ light chain. The antibody is structured as a dimer, ensuring stable binding and specificity to its antigen. This configuration makes Ragistomig suitable for research applications focused on the modulation and study of immune checkpoint pathways.

Anti-IL-13 (H2L6) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody is designed for the precise detection and neutralization of IL-13, a key cytokine involved in inflammatory responses and allergic reactions. It is applicable for use in various immunological assays, including ELISA, Western blotting, and immunohistochemistry, making it a valuable tool for research in immunology and inflammation.

The Anti-IL-15 Antibody (DISC0280) is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-15 (IL-15). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and has a predicted molecular weight of 145 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and pathological roles of IL-15.

Denikitug is a chimeric antibody of the IgG1κ subtype that specifically targets CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Sugemalimab is a fully human, full-length monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that targets programmed death ligand 1 (PD-L1). This antibody exhibits anticancer properties, making it particularly valuable for research into non-small cell lung cancer (NSCLC). Sugemalimab's specificity for PD-L1 enables it to modulate immune responses, which is critical for understanding tumor immune evasion mechanisms in NSCLC.

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3, designed to inhibit the binding of LAG-3 to MHC class II molecules. This interaction blockade enhances T-cell function and may potentiate an anti-tumor immune response. Favezelimab is primarily investigated for its therapeutic potential in colorectal cancer research, particularly in combination with the PD-L1 inhibitor Pembrolizumab, to synergistically enhance immune-mediated tumor suppression.

Rosopatamab (HuJ591) is a humanized IgG1 monoclonal antibody targeting the Prostate-Specific Membrane Antigen (PSMA). This antibody is specifically designed for use in cancer research, with a particular focus on prostate cancer. Rosopatamab can be conjugated to lutetium-177 (177Lu), a low-energy beta-emitting radioisotope, via the bifunctional chelator DOTA-NHS ester. This conjugation facilitates the creation of a radioimmunoconjugate that selectively targets and efficiently eradicates malignant prostate cells. This specificity and efficiency make Rosopatamab an invaluable tool in the development of targeted radiotherapeutic strategies in oncology research.

The Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody specifically designed to target TM4SF1, a transmembrane protein implicated in cell signaling and tumor cell proliferation. For optimal use in experimental controls, it is recommended to utilize Human IgG1 kappa as an isotype control. This antibody serves as a valuable tool in research focused on cancer biology and therapeutic development.

Anti-CLDN6 Antibody (AB3-7) is a humanized monoclonal antibody specifically targeting CLDN6, expressed in Chinese Hamster Ovary (CHO) cells. This antibody is composed of an IgG1 heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 78.02 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control, which matches the antibody's subclass and light chain type. This product is essential for research focusing on the role of CLDN6 in cellular and molecular biology studies.

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody that targets the protective antigen (PA) of Bacillus anthracis. By binding to PA, Raxibacumab effectively inhibits the interaction of the antigen with its cellular receptors, preventing the entry and subsequent toxic effects of the anthrax toxin within host cells. This antibody is utilized primarily in research focused on anthrax prevention and therapy, offering a critical tool for studying the mechanisms of anthrax toxicity and the development of countermeasures.

Setoxaximab is a chimeric humanized antibody of the IgG1-κ isotype, specifically designed to target Shiga toxin type 1. This monoclonal antibody binds with high specificity and affinity to the toxin, potentially neutralizing its effects, which is crucial in studying bacterial pathogenesis and developing therapeutic strategies against Shiga toxin-producing bacterial infections.

Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.

Mirzotamab is an IgG1κ monoclonal antibody specifically designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various tumor cells. This antibody exhibits potent anti-tumor properties. In its conjugated form, mirzotamab is linked to Clezutoclax, a BCL-2 family inhibitor, creating the antibody-drug conjugate (ADC) known as Mirzotamab Clezutoclax (ABBV-155). This ADC is currently under investigation for its efficacy in combination with taxane therapy in the treatment of relapsed or refractory solid tumors, highlighting its potential as a therapeutic in oncological research.

Lulizumab is a humanized recombinant antibody that acts as an antagonist to the CD28 domain. This antibody selectively targets the CD28 signal, effectively inhibiting T-cell activation. In research studies, specifically using a sensitized non-human primate kidney transplantation model, Lulizumab has demonstrated the ability to modulate immune cell responses. When used in combination with Carfilzomib, it has shown potential in prolonging graft survival times, indicating its utility in transplant immunology and immune regulation studies.

The Anti-LAP Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the latency-associated peptide (LAP). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. Researchers seeking an isotype control for this antibody may utilize the Human IgG2 kappa, Isotype Control to ensure specificity and accuracy in their experimental applications. This product is ideal for use in various immunological assays to study the role and regulation of LAP in biological systems.

Anti-GPC3 Antibody (YP7) is a chimeric mouse monoclonal antibody of the IgG1 kappa subclass, specifically designed to target human Glypican 3 (GPC3). For optimal experimental control, the recommended isotype control is Mouse IgG1 kappa, Isotype Control. This antibody is ideal for research applications requiring precise GPC3 targeting.

Zelminemab (AMG-301) is a humanized monoclonal antibody designed to selectively inhibit the PACAP type I (PAC1) receptor. This targeted approach offers potential therapeutic applications in the modulation of pathways involved in various neurological disorders.

Feladilimab (GSK3359609) is a humanized IgG4 monoclonal antibody that functions as an agonist targeting ICOS (CD278). This antibody selectively binds to ICOS-expressing T cells, a critical interaction in the modulation of immune responses. Due to its mechanism of action, Feladilimab is primarily investigated for its potential applications in cancer research, where it may influence T cell activity and tumor immune evasion.

Omoprubart is a humanized monoclonal antibody of the IgG2-G4 κ subtype, specifically targeting the complement component 5 (C5). This antibody is designed for therapeutic interventions in diseases mediated by the complement system.

Placulumab (ART621) is a monoclonal antibody targeting tumor necrosis factor alpha (TNF α), exhibiting potent anti-inflammatory properties. This biologic is designed for the investigation and potential treatment of various inflammatory disorders, including arthritis, where TNF α plays a critical role in disease pathogenesis. Placulumab's specificity for TNF α makes it a valuable tool in research focused on elucidating the mechanisms of inflammation and in clinical settings addressing TNF α-mediated conditions.

Sirtratumab is a human IgG2 monoclonal antibody specifically targeting SLIT and NTRK-like family 6 (Slitrk6). This antibody is designed for use in cancer research, facilitating the investigation of Slitrk6's role and mechanisms in oncogenesis. Sirtratumab's high specificity makes it a valuable tool for detailed studies focusing on the molecular pathways influenced by Slitrk6 in various cancer models.

Ianalumab (VAY-736) is a humanized, decarboxylated monoclonal antibody that specifically targets BAFF-R (B-cell activating factor receptor). This antibody effectively blocks the interaction between BAFF (B-cell activating factor) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated protection from apoptosis. Additionally, Ianalumab promotes antibody-dependent cellular cytotoxicity (ADCC) through the activation of effector cells mediated by the immune receptor tyrosine-based activation motif (ITAM). This dual mechanism of action makes Ianalumab a valuable tool for research into B-cell regulation and autoimmune disease therapies.

Bafisontamab (EMB-01) is a bispecific monoclonal antibody designed for targeted cancer therapy. It simultaneously binds to the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-MET), exhibiting potent antitumor activity. This dual targeting mechanism disrupts critical pathways involved in tumor growth and survival, making Bafisontamab a valuable tool for research in oncology.

Galvokimig is a monoclonal antibody designed to target and neutralize interleukin 13 (IL-13), interleukin 17A (IL-17A), albumin (ALB), and interleukin 17B (IL-17B). This antibody is engineered for high specificity and affinity, making it suitable for use in research studies investigating the roles and interactions of these cytokines in various inflammatory and autoimmune conditions. Galvokimig can be applied in a range of experimental setups, including immunoassays, functional studies, and as a potential therapeutic strategy model.

Gorivitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-MUC16 Antibody (VK8) is a chimeric mouse monoclonal antibody of the IgG1 kappa subclass, designed to specifically target human MUC16. For accurate experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the appropriate isotype control for this antibody.

Greziprubart is a human monoclonal antibody of the IgG1κ isotype designed to specifically target C5a. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Acasunlimab (GEN1046) is a bispecific antibody designed to simultaneously target PD-L1 and 4-1BB. This innovative therapeutic agent facilitates the enhancement of T-cell and NK-cell activity via conditional stimulation of 4-1BB, while consistently inhibiting the PD-1/PD-L1 axis. Acasunlimab is primarily utilized in cancer research, focusing on its potential to modulate immune checkpoint pathways and improve antitumor responses.

Isecarosmab (M-6495) is a monoclonal antibody targeting ADAMTS with a dissociation constant (K_D) of 3.65 pM, indicative of high affinity binding. This antibody exhibits chondroprotective and anti-inflammatory properties, making it valuable in research focused on inflammatory and degenerative joint diseases. Additionally, Isecarosmab has been engineered to bind albumin, which enhances its plasma half-life, thereby potentially improving its therapeutic efficacy and stability in physiological conditions.

Manelimab is a monoclonal antibody designed to selectively inhibit programmed death-ligand 1 (PD-L1), a key molecular target involved in the suppression of the immune response, particularly in the context of tumor evasion. This antibody has potential applications in oncological research and therapeutic interventions aimed at enhancing immune system activity against various cancers.

Cafelkibart is a chimeric IgG1κ monoclonal antibody specifically designed to target CCR8. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Lutikizumab (ABT-981) is a dual variable domain immunoglobulin designed to specifically target and inhibit both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). This monoclonal antibody functions by binding to these cytokines, effectively neutralizing their activity and mitigating their pro-inflammatory effects. Lutikizumab is primarily utilized in research focused on understanding and treating osteoarthritis, providing a valuable tool for investigating the role of IL-1 in inflammatory processes associated with this degenerative disease.

Infliximab, marketed under the name Avakine, is a chimeric monoclonal IgG1 antibody that selectively targets and binds to tumor necrosis factor alpha (TNF-α). By inhibiting the interaction between TNF-α and its receptors (TNFR1 and TNFR2), Infliximab effectively modulates inflammatory responses. This antibody is widely utilized in research focused on autoimmune diseases, chronic inflammatory conditions, and diabetic neuropathy, offering significant potential for elucidating disease mechanisms and therapeutic interventions.

Galegenimab, designated as FHTR 2163, RG 6147, and RO 7171009, is a monoclonal antibody fragment targeting High-temperature requirement A serine peptidase 1 (HTRA1). This antibody fragment is specifically developed for the investigation of its therapeutic potential in age-related macular degeneration (AMD). Galegenimab is utilized primarily in research settings to explore the pathological mechanisms of AMD and to assess its efficacy as a potential treatment modality.

Carlumab (CNTO 888) is a human monoclonal antibody that exhibits high affinity for chemokine ligand 2 (CCL2). This antibody is particularly utilized in the study of cancer mechanisms, with a focus on prostate cancer research. Carlumab's ability to target CCL2 makes it a valuable tool for investigating the role of this chemokine in tumor microenvironments and its potential impact on cancer progression and metastasis.

Lancastotug is a human IgG1 κ monoclonal antibody targeting TIGIT. For optimal experimental control, the use of Human IgG1 kappa Isotype Control is recommended.

Fulranumab is a human IgG2 monoclonal antibody that targets nerve growth factor (NGF), making it a valuable tool for pain research. This antibody binds specifically to NGF, a key mediator in the development and sensation of pain, potentially inhibiting its biological activity and providing insights into pain management mechanisms. Fulranumab is suitable for various experimental applications to explore the role of NGF in pain pathways and therapeutic interventions.

Anrukinzumab (IMA-638) is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of several inflammatory conditions. This antibody has demonstrated efficacy in reducing lung inflammation in cynomolgus monkey models, highlighting its potential utility in pulmonary research. Anrukinzumab is suitable for use in investigations into the mechanisms and treatment of diseases such as ulcerative colitis and asthma, providing a valuable tool for both basic research and therapeutic development.

Lokivetmab is a recombinant monoclonal antibody specifically targeting canine interleukin-31 (IL-31). This antibody is utilized primarily in the study of atopic dermatitis in dogs, providing a valuable tool for understanding the pathophysiology of this condition and the role of IL-31 in canine allergic responses.